cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Relmada Therapeutics Inc
2 own
3 watching
Current Price
$4.06
$0
(0%)
logo-rlmd
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
116.29M
52-Week High
52-Week High
38.68
52-Week Low
52-Week Low
1.81
Average Volume
Average Volume
0.38M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization116.29M
icon52-Week High38.68
icon52-Week Low1.81
iconAverage Volume0.38M
iconDividend Yield--
iconP/E Ratio--
What does the Relmada Therapeutics Inc do?
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Read More
How much money does Relmada Therapeutics Inc make?
News & Events about Relmada Therapeutics Inc.
Market News Video
1month ago
In trading on Wednesday, biotechnology shares were relative leaders, up on the day by about 0.4%. Leading the group were shares of Instil Bio, up about 19.7% and shares of Relmada Therapeutics up about 17.4% on the day...
Zolmax
3 months ago
Exchange Traded Concepts LLC lifted its stake in Relmada Therapeutics, Inc. (NASDAQ:RLMD Get Rating) by 278.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,378 shares of the companys stock after purchasing...
PR Newswire
6 months ago
Relmada Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022 Relmada Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022 PR Newswire CORAL GABLES, Fla., Aug. 5, 2022...
PR Newswire
6 months ago
Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial PR Newswire CORAL GABLES, Fla., July 21, 2022 Company...
PR Newswire
8 months ago
Global Central Nervous System Treatment Market Is Expected to Reach $166 Billion In 2028 Global Central Nervous System Treatment Market Is Expected to Reach $166 Billion In 2028 PR Newswire PALM BEACH, Fla., May 26, 2022 FinancialNewsMedia.com News Commentary PALM BEACH, Fla., May 26, 2022...
Frequently Asked Questions
Frequently Asked Questions
What is Relmada Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Relmada Therapeutics Inc shares?
plus_minus_icon
How can I buy Relmada Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Relmada Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Relmada Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Relmada Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Relmada Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Relmada Therapeutics Inc?
plus_minus_icon
What percentage is Relmada Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Relmada Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$4.06
$0
(0%)
logo-rlmd
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00